Eastling Thomas Wilson 4

What Happened

• Eastling Thomas Wilson, Chief Financial Officer of Gyre Therapeutics (GYRE), was granted multiple derivative awards on May 4, 2026. The grants total 408,757 shares (95,060; 47,530; 11,882; 33,271; 95,060; 92,683; 33,271), each reported at $0.00 per share, indicating option or award grants rather than open‑market purchases or sales. These are awards (Form 4 transaction code "A"), not exercises or sales.

Key Details

• Transaction date: May 4, 2026; Form 4 filed May 6, 2026 (timely filing).
• Total shares awarded: 408,757 derivative shares; each line reported at $0.00.
• Footnotes:
  • F1: One option is fully vested.
  • F2: One option represents a right to purchase 92,683 shares; 1/4 vested on Nov 13, 2025, with the remaining 3/4 vesting in equal monthly installments over the following three years, subject to continued service.
• Shares owned after the transaction: Not specified in the provided filing excerpt.
• Exhibit noted: Exhibit 24 — Power of Attorney.

Context

• These were grant/award transactions (not open‑market buys or sales). For retail investors, grants often reflect compensation or retention incentives rather than immediate insider sentiment; they do not by themselves indicate a buy or sell decision.
• The filing treats these as derivative awards (options/rights to purchase). There is no indication in the filing that any shares were exercised or sold immediately (no cashless exercise or sale noted).